PARP inhibition in homologous-recombination-deficient early-stage breast cancer

被引：0
|
作者：
Pusztai, L. [1 ]
机构：
[1] Yale Sch Med, Yale Canc Ctr, New Haven, CT 06510 USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷 / 01期
关键词：
CARBOPLATIN; VELIPARIB;
D O I：
10.1016/j.annonc.2020.11.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4 / 5
页数：2
相关论文
共 50 条
  • [1] Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
    Raphael Ceccaldi
    Jessica C. Liu
    Ravindra Amunugama
    Ildiko Hajdu
    Benjamin Primack
    Mark I. R. Petalcorin
    Kevin W. O’Connor
    Panagiotis A. Konstantinopoulos
    Stephen J. Elledge
    Simon J. Boulton
    Timur Yusufzai
    Alan D. D’Andrea
    Nature, 2015, 518 : 258 - 262
  • [2] PARP inhibitors for homologous recombination-deficient prostate cancer
    Christenson, Eric S.
    Antonarakis, Emmanuel S.
    EXPERT OPINION ON EMERGING DRUGS, 2018, 23 (02) : 123 - 133
  • [3] Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
    Ceccaldi, Raphael
    Liu, Jessica C.
    Amunugama, Ravindra
    Hajdu, Ildiko
    Primack, Benjamin
    Petalcorin, Mark I. R.
    O'Connor, Kevin W.
    Konstantinopoulos, Panagiotis A.
    Elledge, Stephen J.
    Boulton, Simon J.
    Yusufzai, Timur
    D'Andrea, Alan D.
    NATURE, 2015, 518 (7538) : 258 - U306
  • [4] PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations
    von Werdt, Alexander
    Brandt, Laura
    Scharer, Orlando D.
    Rubin, Mark A.
    JCO PRECISION ONCOLOGY, 2021, 5 : 1639 - 1649
  • [5] PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors
    Pellegrino, B.
    Llop-Guevara, A.
    Pedretti, F.
    Cruz, C.
    Castroviejo, M.
    Cedro-Tanda, A.
    Fasani, R.
    Mateo, F.
    Musolino, A.
    Pujana, M. A.
    Nuciforo, P. G.
    Gros, A.
    Balmana, J.
    O'Connor, M. J.
    Serra Elizalde, V.
    ANNALS OF ONCOLOGY, 2019, 30 : 760 - 760
  • [6] Homologous recombination repair deficient tumor cells exhibit increased radiosensitization by PARP inhibition
    Hageman, F.
    Verhagen, C. V. M.
    Di Carli, A.
    O'Connor, M. J.
    Jonkers, J.
    Verheij, M.
    Van den Brekel, M.
    Vens, C.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S170 - S170
  • [7] Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
    Chopra, Neha
    Tovey, Holly
    Pearson, Alex
    Cutts, Ros
    Toms, Christy
    Proszek, Paula
    Hubank, Michael
    Dowsett, Mitch
    Dodson, Andrew
    Daley, Frances
    Kriplani, Divya
    Gevensleben, Heidi
    Davies, Helen Ruth
    Degasperi, Andrea
    Roylance, Rebecca
    Chan, Stephen
    Tutt, Andrew
    Skene, Anthony
    Evans, Abigail
    Bliss, Judith M.
    Nik-Zainal, Serena
    Turner, Nicholas C.
    NATURE COMMUNICATIONS, 2020, 11 (01)
  • [8] Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
    Neha Chopra
    Holly Tovey
    Alex Pearson
    Ros Cutts
    Christy Toms
    Paula Proszek
    Michael Hubank
    Mitch Dowsett
    Andrew Dodson
    Frances Daley
    Divya Kriplani
    Heidi Gevensleben
    Helen Ruth Davies
    Andrea Degasperi
    Rebecca Roylance
    Stephen Chan
    Andrew Tutt
    Anthony Skene
    Abigail Evans
    Judith M. Bliss
    Serena Nik-Zainal
    Nicholas C. Turner
    Nature Communications, 11
  • [9] PARP trapping beyond homologous recombination and platinum sensitivity in breast cancer
    Murai, Junko
    CANCER SCIENCE, 2021, 112 : 519 - 519
  • [10] AsiDNA induce tumor sensitivity to PARP inhibitors in homologous recombination proficient breast cancer AsiDNA induce tumor sensitivity to PARP inhibitors in homologous recombination proficient breast cancer
    Dutreix, Marie
    Jdey, Wael
    Thierry, Sylvain
    Kuperstein, Inna
    Dixon, Graham
    CANCER RESEARCH, 2017, 77
12345